Long Term Outcomes of Hypertensive Kidney Donors
Houston Methodist Hospital, Houston, TX
Meeting: 2020 American Transplant Congress
Abstract number: LB-010
Keywords: Donation, Hypertension, Kidney transplantation, Living donor
Session Information
Session Name: Poster Session A: Late Breaking
Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
Location: Virtual
*Purpose: Many people with hypertension are excluded from kidney donation fearing that hypertension is a major cause of CKD and its impact maybe magnified after nephrectomy. Such practice is not fully supported by strong evidence and may deprive some the benefit of a live donor transplant.
*Methods: In a retrospective analysis of 8721 ethnically diverse kidney donors of whom 904 were hypertensive at donation, we compared long-term outcomes of hypertensive kidney donors to those without hypertension at the time of donation. All donations took place 1963-2007. Study outcomes were mortality, cardiovascular disease, proteinuria, and ESRD.
*Results: Median age was 39 years, 56.2% were women, 85% were non-Hispanic white, and 80.5% were related donors. At donation, 904 donors were hypertensive; receiving antihypertensive medications (n=251) or had a blood pressure >140/90 mmHg (n=653). Hypertensive donors were older, 58.2% were <50 years old and had a lower eGFR at donation. After 7 ±10 years, an additional 26% of donors developed hypertension. Donors with new hypertension were younger at donation and were less likely to be related to the recipient. The 30-year cumulative incidence of ESRD was 213/10000 in hypertensive donors vs. 342/10000 in normotensive donors. The multivariable risk of mortality, CVD and proteinuria were comparable in normotensive and hypertensive donors. In total, 5 hypertensive donors and 39 normotensive donors developed ESRD 19.2 ±10.3 years after donation, aHR 0.42 (0.08-2.07), p=.29 in the Cox model and aOR 1.04 (0.36-3.0), p=0.95 in the multiple regression model. Sensitivity analysis using the new definition of hypertension (>130/80) yielded similar results.
*Conclusions: Kidney donors with hypertension do not appear to incur higher mortality, CVD, or ESRD. Wider acceptance of well screened hypertensive kidney donors appears reasonable and could safely expand live donation.
No HTN | HTN | ||||
Outcomes | Time to event, years | n (%) | n (%) | Adjusted HR (95% CI) | p-value |
Mortality | 22.2 (±9.3) | 341 (10.1) | 50 (17.8) | 0.73 (0.44, 1.24) | 0.25 |
Cardiovascular Disease | 17.8 (±9.4) | 630 (18.8) | 78 (28.0) | 0.82 (0.55, 1.23) | 0.34 |
Proteinuria | 15.3 (±10.3) | 472 (16.4) | 56 (24.2) | 1.21 (0.86, 1.69) | 0.28 |
eGFR <30 or ESRD | 19.0 (+12.4) | 60 (1.8) | 13 (4.6) | 1.03 (0.44, 2.43) | 0.95 |
To cite this abstract in AMA style:
Ibrahim H, Hebert S, Adrogue HE, Nguyen DT, Graviss EA, Gaber A, Matas A. Long Term Outcomes of Hypertensive Kidney Donors [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-outcomes-of-hypertensive-kidney-donors/. Accessed November 22, 2024.« Back to 2020 American Transplant Congress